Block Grant R43HL088871

This three-year, four hundred thirty-five thousand eight hundred forty-five dollar ($435,845) Project Grant from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems will support Carnegie Mellon University's efforts to advance biom anufacturing of vascularized adipose tissues. Specifically, the university aims to address engineering challenges in producing large, high-density human adipose tissues with integrated, perfusable vascular...

Federal Project Grant Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded Microvascular Tissues, Inc. a $700,000 Project Grant on September 17, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the efficacy of its Microvascular Tissue Graft (MVASC) treatment in rat models of diabetic peripheral neuropathy (DPN). MVASC is a novel human structural allograft consisting of lyophilized and terminally...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant totaling $169,160 under the Cardiovascular Diseases Research program (CFDA 93.837), effective December 1, 2026, with completion targeted for May 31, 2029. The project deliverables focus on engineering hypoimmunogenic induced pluripotent stem cell (iPSC)-derived vascular cells designed to overcome immune rejection barriers in allogeneic transplantation...

Yale University received a $455,604 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on May 1, 2026, with completion targeted for April 30, 2028. The grant funds development of a novel high-density lipoprotein (HDL)-mediated RNA delivery platform (C15-9-900 lipid nanoparticle) designed to provide unprecedented endothelial cell-specific targeting for treating vascular diseases driven by endothelial dysfunction. The platform utilizes...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded University of Massachusetts Medical School $1.499 million under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of perivascular adipose tissue (PVAT) in atherosclerotic cardiovascular disease (ASCVD). The project, initiated September 1, 2025, and extending through June 30, 2030, aims to characterize molecular and functional differences between PVAT surrounding the right...

Federal Project Grant Award Summary Zvelt Therapeutics Inc. received a $974,604 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective September 9, 2025, with completion targeted for July 31, 2028. The grant funds development of REC2-LEPTIN/DUAL CASSETTE, a recombinant adeno-associated virus (rAAV)-based gene therapy designed to treat lipodystrophy...

Federal Grant Award Summary Boston Children's Hospital received a $139,822 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 4, 2026, with an ultimate completion date of April 30, 2028. The award funds research into the mechanisms of endothelial cell differentiation during vasculogenesis, specifically investigating how the ETV2 transcription factor drives specification and arteriovenous...

Endoshape, Inc. was awarded a $370,938 project grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop radiopaque shape memory polymers for neurovascular embolotherapy applications. The Cardiovascular Diseases Research program aims to support heart and vascular research, including through competitive research training grants. Under this award, Endoshape will develop new radiopaque shape memory polymer materials incorporated into embolic coils....

This Project Grant award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), provides $275,000 to Mellicell Inc. to develop an industrial-scale technology for drug development using mature human fat cells. The broader impact of this SBIR Phase I project is to enable the discovery and development of next-generation therapeutics for obesity and associated medical conditions that can be treated through weight loss. The award will...

This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, provides $914,900 to Ship Of Theseus LLC under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports preclinical development of a nuclear-targeting biologic to safely increase stem cell expansion in vivo and accelerate recovery from neutropenia following chemotherapy and bone marrow transplant. Specifically, the grant will advance a patented mutant...